单唾液酸四己糖神经节苷脂治疗新生儿缺氧缺血性脑病效果观察

    Effect of monosialotetrahexosylganglioside in treatment of neonatal hypoxic-ischemic encephalopath

    • 摘要: 目的: 观察单唾液酸四己糖神经节苷脂(GM1)治疗新生儿缺氧缺血性脑病(HIE)的临床疗效。方法: 将44例HIE患儿随机分为对照组和治疗组,每组22例。对照组采用常规治疗联合胞二磷胆碱,治疗组在对照组治疗基础上加用GM1。观察并比较2组患儿的临床表现、恢复情况以及治疗前后新生儿神经行为评分(NBNA)。结果: 治疗组和对照组的临床症状改善总有效率分别为95.45%和63.64%,差异有统计学意义(P < 0.05);治疗组治疗10~14天后NBNA恢复优于对照组(P <0.01)。结论: 早期联合应用GM1治疗HIE效果确切,能改善神经系统功能障碍。

       

      Abstract: Objective: To observe the efficacy of monosialotetrahexosylganglioside(GM1) in treatment of neonatal hypoxic-ischemic encephalopathy(HIE). Methods: Forty-four cases of neonatal HIE were evenly divided into two groups. The control group were administered the conventional therapy and citicoline; the treatment group,in addition to the therapy of the control group,received GM1. The clinical manifestation and recovery of the children in the two groups were observed and recorded. The neonatal behavioral neurological assessment (NBNA) scores were compared between the two groups before and after treatment. Results: The total response rates of the treatment group and the control group were 95.45% and 63.64%,respectively (P < 0.05). The NBNA scores in the treatment group were higher than that in the control group at 10-14 days during the treatment (P < 0.01). Conclusions: Early application of neonatal GM1 can effectively improve the nervous system dysfunction of the children with HIE.

       

    /

    返回文章
    返回